Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Metrizamide (Amipaque) has been used as the contrast medium for angiography in neuroradiological investigations. Solutions containing 280 mgI/ml. are well tolerated and produce good contrast. The most important difference from previously used contrast media is the lack of pain when injections are made selectively or super-selectively into the external carotid artery and its branches, or into the spinal arteries.
 ...
PMID:[Cerebral and spinal angiography with metrizamide (amipaque) (author's transl)]. 15 63

The degree of pain produced by Amipaque 260 and Isopaque 260 at intraosseous phlebography in patients with varicose ulcerations in the ankle region was compared. Amipaque produced less pain than Isopaque. No complications or side-effects occurred during the observation period of about one year.
 ...
PMID:Amipaque as contrast medium for intraosseous phlebography. 35 57

Metrizamide, a non-ionic contrast medium of low osmolality was compared with meglumine ioxithalamate, the ionic angiographic contrast medium currently in use in our department in a double-blind study. Criteria upon which the comparison was based were: 1) the pain reaction of the patient upon intra-arterial contrast injection, 2) bradycardial reactions upon common carotid injection and 3) the quality of the contrast image. Metrizamide induced significantly less painful sensations than meglumine ioxithalamate in those vessels in which injections of contrast medium are frequently painful (external carotid artery, vertebral artery). No significant difference in the degree of bradycardia was caused by the two contrast media. The degree of bradycardia was also found to be poorly reproducible upon successive injections of the same contrast medium in the same patient, thus raising questions as to the suitability of this method for determining the toxicity of the contrast medium. The quality of the angiograms obtained did not differ significantly with the two media. Spasm, when it occurred during selective external carotid injections, was found to be independent of the contrast agent used, being correlated instead with the depth of distal advance of the catheter tip into the external carotid. Of the 51 patients included in the study, two patients suffered transient neurological deficit after angiography with metrizamide, and one patient suffered a permanent hemiplegia after angiography with meglumine ioxithalamate.
 ...
PMID:Comparative evaluation of metrizamide and meglumine ioxithalamate in angiography of the vessels of the head and neck. 36 33

The authors report their initial experience with Amipaque (metrizamide) in hysterosalpingography. Amipaque was compared to Isopaque Cerebral in 37 patients, using a double-blind design. Excellent radiographs were obtained with both agents. No statistically significant difference in discomfort and pain was found up to 24 hours after the procedure. However, the aftereffects indicate that Amipaque might be less irritating to the pelvic peritoneal cavity.
 ...
PMID:Hysterosalpingography with Amipaque. 37 Aug 94

The non-ionic contrast medium metrizamide (Amipaque) was compared in animal experiments with diatrizoate, iothalamate and metrizoate. Vasodilatory effects, acute intravenous toxicity and effects on red blood cells, pulmonary arterial pressure, endothelium and heart were all less after metrizamide than after the ionic media. This motivated clinical trial of metrizamide for angiography, which demonstrated that metrizamide produced less pain than the ionic monomeric media in femoral as well as in other types of angiography.
 ...
PMID:Angiography with metrizamide. Animal experiments and preliminary clinical experiences. 40 Sep 7

In two studies 267 consecutive patients with suspected venous thrombosis were examined 125I-fibrinogen uptake test at phebography. In 161 patients meglumine metrizoate (Isopaque Cerebral) and in 106 patients metrizamide (Amipaque) was used as contrast medium. The quality of the examinations was equal in the two groups. During the examinations most of the patients examined with meglumine metrizoate had symptoms from the calf described as a cramp-like pain. Only few of the patients examined with metrizamide had such symptoms. In the two groups 47 patients examined with meglumine metrizoate and 41 examined with metrizamide had normal phlebography as well as initially normal 125I-fibrinogen uptake test. After phlebography, 29 of the patients in the first group had a significant rise in fibrinogen uptake while such a rise was not found in patients from the second group. Rephlebography showed fresh deep vein thrombosis in 7 out of 9 patients examined with meglumine metrizoate indicating that thrombosis could be provoked in as many as about half the patients with this high osmolar contrast medium. We have now used metrizamide in about 400 patients without any side-effects.
 ...
PMID:Side-effects at phlebography with ionized and non-ionized contrast medium. 49 20

Amipaque 280 mg I/ml and Conray meglumine 282 mg I/ml have been compared in a double-bind trial in cerebral angiography. Altogether 55 cerebral artery branches have been examined in 21 patients, who served as their own controls. The effect of the contrast injections on the intra-arterial blood pressure, pulse rate, ECG, circulatory rate and the patients' reactions were recorded under standardized conditions. The quality of the films was also evaluated. No significant difference in the cardiovascular effects of the two contrast media was found. There was a significant difference in favour of Amipaque in the discomfort of the patients--less pain and sensation of warmth. No serious side effects were observed.
 ...
PMID:Clinical testing of Conray meglumine and Amipaque in cerebral angiography. 51 99

Amipaque is found to be very suitable for dacryocystography because it has a low osmolality and high viscosity, and is in addition the only aqueous contrast medium currently available which in higher concentrations does not cause pain when applied to the conjunctival sac.
 ...
PMID:Dacryocystography with amipaque (metrizamide). 57 72

Amipaque 280 mg I/ml was compared to Isopaque Cerebral 280 mg I/ml for common carotid injection in twenty patients in a double blind trial. Simple comparison was also performed in examinations with selective external carotid injections. The reaction of the patients to the common carotid injection was mild on the whole but Amipaque caused significantly less discomfort than Isopaque. Selective external carotid injection of Amipaque caused very little discomfort while most patients complained of severe pain when Isopaque was used. No serious side-effect was observed.
 ...
PMID:Clinical testing of Amipaque for cerebral angiography. 66 85

In 20 patients the non-ionic Amipaque (metrizamide) and the ionic Isopaque Cerebral (meglumine/calcium-metrizoate) were injected into the femoral, brachial internal iliac or external carotid arteries. Strain gauge plethysmography of the lower leg demonstrated less increase in blood flow following injections of Amipaque (25%) than following injections of Isopaque Cerebral (95%). None of the 20 patients complained of pain following injection af Amipaque; 15 experienced pain following Isopaque Cerebral.
 ...
PMID:Metrizamide in angiography I. Femoral angiography. 87 90


1 2 3 4 Next >>